Table 3.

Base-case analysis deterministic results^a

	Vericiguat + PSoCT	PSoCT	Difference
Total LYs per patient	4.18	3.82	0.35
Alive, prior to HFH	2.93	2.54	0.38
Alive, during or post HFH	1.25	1.28	−0.03
Total QALYs per patient	3.34	3.05	0.28
Alive, prior to HFH	2.34	2.04	0.31
Alive, during or post HFH	0.99	1.02	−0.02
Number of events per 1000 patients
HFH	681	700	−19
CV mortality	427	440	−13
Total costs per patient	$60,228	$36,907	$23,322
Drug acquisition	$25,686	$3,160	$22,526
HFH	$7093	$7295	−$202
Routine care	$19,430	$18,337	$1093
Terminal care	$8020	$8,115	−$95
Incremental cost per QALY gained per patient			$82,448
Incremental cost per LY gained per patient			$65,988

CV cardiovascular, HFH heart failure hospitalization, LYs life-years, PSoCT prior standard-of-care therapies, QALYs quality-adjusted life-years

^aValues were rounded to the nearest number